The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01475825




Registration number
NCT01475825
Ethics application status
Date submitted
17/11/2011
Date registered
21/11/2011
Date last updated
26/03/2019

Titles & IDs
Public title
A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol
Scientific title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Continuation Period to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol
Secondary ID [1] 0 0
2011-001480-42
Secondary ID [2] 0 0
MIPO3801011
Universal Trial Number (UTN)
Trial acronym
FOCUS FH
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hypercholesterolemia 0 0
Heterozygous Familial 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Other metabolic disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - mipomersen sodium 200 mg
Treatment: Drugs - Placebo
Treatment: Drugs - mipomersen sodium 70 mg

Experimental: Regimen A: Mipomersen - Subcutaneous injection of mipomersen 200 mg once weekly

Placebo Comparator: Regimen A: Placebo - Placebo matching subcutaneous injection once weekly.

Experimental: Regimen B: Mipomersen - Subcutaneous injection of mipomersen 70 mg thrice weekly.

Placebo Comparator: Regimen B: Placebo - Placebo matching subcutaneous injection thrice weekly.


Treatment: Drugs: mipomersen sodium 200 mg
Subcutaneous mipomersen 200 mg once weekly

Treatment: Drugs: Placebo
Placebo vehicle for subcutaneous injection.

Treatment: Drugs: mipomersen sodium 70 mg
Subcutaneous mipomersen 70 mg thrice weekly

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percent Change From Baseline To Primary Endpoint Visit (PET) In LDL-C In Cohort 1 - The percent change from baseline to PET in LDL-C was measured in Cohort 1, which included participants with severe heterozygous familial hypercholesterolemia (HeFH). Severe HeFH was defined as LDL-C levels =200 mg/deciliter (dL) plus the presence of coronary heart disease (CHD)/risk equivalents or LDL-C levels =300 mg/dL regardless of the presence of CHD/risk equivalents.
Timepoint [1] 0 0
Baseline and Week 61
Secondary outcome [1] 0 0
Percent Change From Baseline To PET In LDL-C In Cohort 2 - The percent change from baseline to PET in LDL-C was measured in Cohort 2, which included participants with HeFH with LDL-C levels =160 mg/dL and <200 mg/dL, plus the presence of CHD/risk equivalents.
Timepoint [1] 0 0
Baseline, PET (up to 60 weeks)
Secondary outcome [2] 0 0
Percent Change From Baseline To PET In Apolipoprotein B (Apo B) In Cohort 1 - The percent change from baseline to PET in Apo B was measured in participants in Cohort 1 with HeFH during the Blinded Treatment Period.
Timepoint [2] 0 0
Baseline and Week 61
Secondary outcome [3] 0 0
Percent Change From Baseline To PET In Apolipoprotein B (Apo B) In Cohort 2 - The percent change from baseline to PET in Apo B was measured in participants in Cohort 2 with HeFH during the Blinded Treatment Period.
Timepoint [3] 0 0
Baseline and Week 61
Secondary outcome [4] 0 0
Percent Change From Baseline To PET in Lipoprotein (a) In Cohort 1 - The percent change from baseline to PET in Lipoprotein A1 was measured in participants in Cohort 1 with HeFH during the Blinded Treatment Period.
Timepoint [4] 0 0
Baseline and Week 61
Secondary outcome [5] 0 0
Percent Change From Baseline To PET in Lipoprotein (a) In Cohort 2 - The percent change from baseline to PET in Lipoprotein A1 was measured in participants in Cohort 2 with HeFH during the Blinded Treatment Period.
Timepoint [5] 0 0
Baseline and Week 61

Eligibility
Key inclusion criteria
- Diagnosis of severe hypercholesterolemia (LDL-C =300 mg/dL (7.77 mmol/L) or LDL-C =200
mg/dL (5.18 mmol/L) with documented coronary heart disease (CHD) or CHD risk
equivalents, or diagnosis of Heterozygous Familial Hypercholesterolemia and LDL-C =160
mg/dL (4.14 mmol/L) and <200 mg/dL (5.18 mmol/L))

- On stable, maximally tolerated, statin therapy for at least 12 weeks or if statin
intolerant, on at least 1 medication from another class of hypolipidemic agents (i.e.,
bile acid sequestrants, niacin/nicotinic acid, cholesterol absorption inhibitors,
fibrates).

- On stable, low fat diet for 12 weeks

- Body mass index (BMI) =40 kg/m2 and stable weight for > 6 weeks
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Significant health problems in the recent past including heart attack, stroke,
coronary syndrome, unstable angina, heart failure, significant arrhythmia,
hypertension, blood disorders, liver disease, cancer, digestive disorders, Type I
diabetes, or uncontrolled Type II diabetes

- Apheresis within 3 months prior to Screening or expected to start apheresis during the
treatment phase

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Perth
Recruitment hospital [2] 0 0
- South Brisbane
Recruitment postcode(s) [1] 0 0
- Perth
Recruitment postcode(s) [2] 0 0
- South Brisbane
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Indiana
Country [5] 0 0
United States of America
State/province [5] 0 0
Kansas
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Minnesota
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
Nebraska
Country [11] 0 0
United States of America
State/province [11] 0 0
New Jersey
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
Oregon
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
South Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Virginia
Country [19] 0 0
Argentina
State/province [19] 0 0
Ciudad Autonoma de Buenos Aires
Country [20] 0 0
Argentina
State/province [20] 0 0
Cordoba
Country [21] 0 0
Belgium
State/province [21] 0 0
Edegem
Country [22] 0 0
Belgium
State/province [22] 0 0
Haine St. Paul
Country [23] 0 0
Belgium
State/province [23] 0 0
Leuven
Country [24] 0 0
Brazil
State/province [24] 0 0
Rio de Janeiro
Country [25] 0 0
Brazil
State/province [25] 0 0
Sao Paulo
Country [26] 0 0
Canada
State/province [26] 0 0
Quebec
Country [27] 0 0
Croatia
State/province [27] 0 0
Osijek
Country [28] 0 0
Croatia
State/province [28] 0 0
Zagreb
Country [29] 0 0
Czechia
State/province [29] 0 0
Hradec Kralove
Country [30] 0 0
Czechia
State/province [30] 0 0
Praha 1
Country [31] 0 0
Denmark
State/province [31] 0 0
Aarhus
Country [32] 0 0
Denmark
State/province [32] 0 0
Viborg
Country [33] 0 0
Germany
State/province [33] 0 0
Aachen
Country [34] 0 0
Germany
State/province [34] 0 0
Berlin
Country [35] 0 0
Germany
State/province [35] 0 0
Freiburg
Country [36] 0 0
Germany
State/province [36] 0 0
Hamburg
Country [37] 0 0
Germany
State/province [37] 0 0
Heidelberg
Country [38] 0 0
Germany
State/province [38] 0 0
Koeln
Country [39] 0 0
Germany
State/province [39] 0 0
Magdeburg
Country [40] 0 0
Greece
State/province [40] 0 0
Ioannina
Country [41] 0 0
Greece
State/province [41] 0 0
Kallithea
Country [42] 0 0
Hong Kong
State/province [42] 0 0
Hong Kong
Country [43] 0 0
Hungary
State/province [43] 0 0
Baja
Country [44] 0 0
Hungary
State/province [44] 0 0
Budapest
Country [45] 0 0
Hungary
State/province [45] 0 0
Debrecen
Country [46] 0 0
India
State/province [46] 0 0
New Delhi
Country [47] 0 0
Israel
State/province [47] 0 0
Holon
Country [48] 0 0
Israel
State/province [48] 0 0
Kfar Saba
Country [49] 0 0
Israel
State/province [49] 0 0
Ofakim
Country [50] 0 0
Italy
State/province [50] 0 0
Bologna
Country [51] 0 0
Italy
State/province [51] 0 0
Napoli
Country [52] 0 0
Italy
State/province [52] 0 0
Padova
Country [53] 0 0
Italy
State/province [53] 0 0
Palermo
Country [54] 0 0
Italy
State/province [54] 0 0
Pisa
Country [55] 0 0
Italy
State/province [55] 0 0
Roma
Country [56] 0 0
Korea, Republic of
State/province [56] 0 0
Seoul
Country [57] 0 0
Malaysia
State/province [57] 0 0
Kuala Lumpur
Country [58] 0 0
Malaysia
State/province [58] 0 0
Kubang Kerian
Country [59] 0 0
Netherlands
State/province [59] 0 0
Alkmaar
Country [60] 0 0
Netherlands
State/province [60] 0 0
Amsterdam
Country [61] 0 0
Netherlands
State/province [61] 0 0
Maastricht
Country [62] 0 0
Netherlands
State/province [62] 0 0
Nijmegen
Country [63] 0 0
Netherlands
State/province [63] 0 0
Utrecht
Country [64] 0 0
Netherlands
State/province [64] 0 0
Waalwijk
Country [65] 0 0
New Zealand
State/province [65] 0 0
Christchurch
Country [66] 0 0
Norway
State/province [66] 0 0
Bodo
Country [67] 0 0
Norway
State/province [67] 0 0
Oslo
Country [68] 0 0
Norway
State/province [68] 0 0
Sandefjord
Country [69] 0 0
Poland
State/province [69] 0 0
Bialystok
Country [70] 0 0
Poland
State/province [70] 0 0
Gdansk
Country [71] 0 0
Poland
State/province [71] 0 0
Katowice
Country [72] 0 0
Poland
State/province [72] 0 0
Krakow
Country [73] 0 0
Poland
State/province [73] 0 0
Naleczow
Country [74] 0 0
Poland
State/province [74] 0 0
Poznan
Country [75] 0 0
Poland
State/province [75] 0 0
Sopot
Country [76] 0 0
Poland
State/province [76] 0 0
Szczecin
Country [77] 0 0
Poland
State/province [77] 0 0
Warszawa
Country [78] 0 0
Poland
State/province [78] 0 0
Wroclaw
Country [79] 0 0
Russian Federation
State/province [79] 0 0
Barnaul
Country [80] 0 0
Russian Federation
State/province [80] 0 0
Kemerovo
Country [81] 0 0
Russian Federation
State/province [81] 0 0
Moscow
Country [82] 0 0
Russian Federation
State/province [82] 0 0
Novosibirsk
Country [83] 0 0
Russian Federation
State/province [83] 0 0
Petrozavodsk
Country [84] 0 0
Russian Federation
State/province [84] 0 0
Ryazan
Country [85] 0 0
Russian Federation
State/province [85] 0 0
Saint Petersburg
Country [86] 0 0
Russian Federation
State/province [86] 0 0
St-Petersburg
Country [87] 0 0
Russian Federation
State/province [87] 0 0
St. Petersburg
Country [88] 0 0
Russian Federation
State/province [88] 0 0
Tomsk
Country [89] 0 0
Russian Federation
State/province [89] 0 0
Yaroslavl
Country [90] 0 0
South Africa
State/province [90] 0 0
Cape Town
Country [91] 0 0
South Africa
State/province [91] 0 0
Pretoria
Country [92] 0 0
Spain
State/province [92] 0 0
Madrid
Country [93] 0 0
Sweden
State/province [93] 0 0
Stockholm
Country [94] 0 0
Taiwan
State/province [94] 0 0
New Taipei City
Country [95] 0 0
Taiwan
State/province [95] 0 0
Taipei
Country [96] 0 0
Turkey
State/province [96] 0 0
Ankara
Country [97] 0 0
Turkey
State/province [97] 0 0
Istanbul
Country [98] 0 0
Turkey
State/province [98] 0 0
Izmir
Country [99] 0 0
Turkey
State/province [99] 0 0
Sivas
Country [100] 0 0
Ukraine
State/province [100] 0 0
Ivano-Frankivsk
Country [101] 0 0
Ukraine
State/province [101] 0 0
Kiev
Country [102] 0 0
Ukraine
State/province [102] 0 0
Kyiv
Country [103] 0 0
Ukraine
State/province [103] 0 0
Odesa
Country [104] 0 0
Ukraine
State/province [104] 0 0
Odessa
Country [105] 0 0
United Kingdom
State/province [105] 0 0
Birmingham
Country [106] 0 0
United Kingdom
State/province [106] 0 0
Cardiff
Country [107] 0 0
United Kingdom
State/province [107] 0 0
Liverpool
Country [108] 0 0
United Kingdom
State/province [108] 0 0
London
Country [109] 0 0
United Kingdom
State/province [109] 0 0
Manchester
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Oldham

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Kastle Therapeutics, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Primary objective:

Determine whether mipomersen (ISIS 301012) significantly reduces atherogenic lipid levels in
patients with severe heterozygous familial hypercholesterolemia (severe HeFH), defined as
low-density lipoprotein cholesterol (LDL-C) levels =200 mg/dL plus the presence of coronary
heart disease (CHD)/risk equivalents or LDL-C levels =300 mg/dL regardless of the presence of
CHD/risk equivalents (referred to as Cohort 1) compared to placebo. Two different mipomersen
dosing regimens will be studied: subcutaneous (SC) mipomersen 200 mg once weekly versus
placebo, and SC mipomersen 70 mg thrice weekly versus placebo.

Secondary Objectives:

- Determine whether there are qualitative differences between the safety profiles of the 2
dosing regimens and placebo in Cohort 1, patients with HeFH with LDL-C levels =160 mg/dL
and <200 mg/dL plus the presence of CHD/risk equivalents (referred to as Cohort 2), and
the overall study population

- Determine whether there are qualitative differences between the tolerability of the 2
dosing regimens and placebo in Cohort 1, Cohort 2, and the overall study population

- Further characterize the pharmacokinetics (PK) of the 2 dosing regimens in Cohort 1,
Cohort 2, and the overall study population

- Determine whether the 2 mipomersen dosing regimens significantly reduce atherogenic
lipid levels in Cohort 2 compared to placebo

- Obtain additional data regarding ongoing safety and efficacy of mipomersen in patients
with FH and inadequately controlled LDL-C who complete the primary efficacy assessment
visit (PET) in the Blinded Treatment Period and continue treatment in Open-Label
Continuation Period
Trial website
https://clinicaltrials.gov/show/NCT01475825
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Monitor
Address 0 0
Genzyme, a Sanofi Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications